Economic impact of pharmaceutical interventions in a medium complexity Brazilian university hospital
DOI:
https://doi.org/10.1590/s2175-97902022e201198Keywords:
Pharmaceutical intervention, Direct costs, Economic impact, Hospital settingAbstract
Clinical pharmacists have been increasing their participation mainly through actions aimed at patient care, with international studies demonstrating favorable cost-benefit ratio from pharmacists interventions. However, there are few studies carried out in Brazil about the subject. This study aims to assess the economic impact of pharmaceutical interventions (PIs) in a hospital setting performed in October 2018. Each performed PI was registered and associated with the direct cost of drugs for economic impact analysis. A total of 185 PIs were evaluated, comprising 106 patients. The most intervened drugs were antibiotics, presenting the greatest economic impact, R$2,370. The total economic impact was R$2,578, mainly in the Pediatric Intensive Care Unit that represented R$1,701. Regarding the economic impact by PI as the “Suspension of drug without indication” saved R$1,360 while the “Inclusion of required drugs” cost R$807. It was estimated that the savings would be R$30,936 and, if PIs were performed at day zero, the savings would be R$79,728 per year. An average of 1.75 PI per patient was performed with an economic impact of R$14 per PI. Our results showed that clinical pharmacist’s role in the evaluation of pharmacotherapy is important for patients’ health and represents a positive economic impact.
Downloads
References
Aguiar KD, Santos JM, Cambrussi MC, Picolotto S, Carneiro MB. Segurança do paciente e o valor da intervenção farmacêutica em um hospital oncológico. Einstein (São Paulo). 2018;16(1):1-7.
American College of Clinical Pharmacy (A.C.C.P.). The definition of clinical pharmacy. Pharmacotherapy. 2008;28(6):816-7.
Boutin K, Nevers W, Gorman SK, Slavik RS, Martinusen DJ, Lo C. Development of intervention-related quality indicators for renal clinical pharmacists using a modified Delphi approach. Int J Clin Pharm Pract. 2019;27(5):436-42.
Brasil. Ministério da Saúde, Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde (a). Relação Nacional de Medicamentos Essenciais 2020. [Online]. Brasília (DF). Ministério da Saúde, 2019a. [cited 2020 Jan 10]. 219p. Available from: Available from: http://conitec.gov.br/images/Rename-2020.pdf
» http://conitec.gov.br/images/Rename-2020.pdf
Brasil. Ministério da Saúde, Secretaria de Vigilância em Saúde (b). Vigilância em saúde no Brasil 2003-2019: da criação da Secretaria de Vigilância em Saúde aos dias atuais. [Online]. Brasília(DF).Ministério da Saúde,2019b.[cited 2020 Jan 10].156p. Available from: Available from: https://portalarquivos2.saude.gov.br/images/ pdf/2019/setembro/25/boletim-especial-21ago19-web.pdf? f bclid=IwAR3qTQYyo5tG7dYLNXWfj4ymtmIAoJtlolbT nwToAPConwrDn0Vpv0kyzvo
» https://portalarquivos2.saude.gov.br/images/ pdf/2019/setembro/25/boletim-especial-21ago19-web.pdf? f bclid=IwAR3qTQYyo5tG7dYLNXWfj4ymtmIAoJtlolbT nwToAPConwrDn0Vpv0kyzvo
Brasil. Pan-American Health Organization. Atenção Farmacêutica no Brasil: “Trilhando Caminhos”. Relatório 2001 - 2002. [Online]. Brasília (DF). Pan-American Health Organization, 2002. [cited 2020 Jan 10]. 45p. Available from: Available from: https://www.paho.org/bra/index.php?option=com_ docman&view=download&alias=790-atencao-farmaceutica-no- brasil- t r i lhando- caminhos-relatorio-2001-2002 - 0&category_slug=vigilancia-sanitaria-959&Itemid=965
» https://www.paho.org/bra/index.php?option=com_ docman&view=download&alias=790-atencao-farmaceutica-no- brasil- t r i lhando- caminhos-relatorio-2001-2002 - 0&category_slug=vigilancia-sanitaria-959&Itemid=965
Cazarim MD, Rodrigues JP, Calcini PS, Einarson TR, Pereira LR. Cost-benefit analysis of pharmacist interventions over 36 months in a university hospital. Rev Saúde Pública. 2020;54:94.
Correia KKL, Rego ML, Júnior MR, Marques RA. Farmácia clínica: importância deste serviço no cuidado à saúde. Bol Inf Geum. 2017;8(3):7.
Daupin J, Perrin G, Lhermitte-Pastor C, Loustalot MC, Pernot S, Savoldelli V, et al. Pharmaceutical interventions to improve safety of chemotherapy-treated cancer patients: A cross-sectional study. J Oncol Pharm Pract. 2019;25(5):1195-203.
De Rijdt T, Willems L, Simoens S. Economic effects of clinical pharmacy interventions: a literature review. Am J Health Syst Pharm. 2008;65(12):1161-72.
Finatto RB. Intervenção farmacêutica como indicador de qualidade da assistência hospitalar. [dissertation]. Porto Alegre, RS, Brazil: Universidade Federal do Rio Grande do Sul. 2011.
Gallagher J, McCarthy S, Byrne S. Economic evaluations of clinical pharmacist interventions on hospital inpatients: a systematic review of recent literature. Int J Clin Pharm. 2014;36(6):1101-14.
Jourdan JP, Muzard A, Goyer I, Ollivier Y, Oulkhouir Y, Henri P, et al. Impact of pharmacist interventions on clinical outcome and cost avoidance in a university teaching hospital. Int J Clin Pharm . 2018;40(6):1474-81.
Klopotowska JE, Kuiper R, van Kan HJ, de Pont AC, Dijkgraaf MG, Lie-A-Huen L, et al. On-ward participation of a hospital pharmacist in a Dutch intensive care unit reduces prescribing errors and related patient harm: an intervention study. Crit care. 2010;14(5):R174.
Kwon JW, Park HY, Kim YJ, Moon SH, Kang HY. Cost-effectiveness of pharmaceutical interventions to prevent osteoporotic fractures in postmenopausal women with osteopenia. J Bone Metab. 2016;23(2):63-77.
Mongaret C, Quillet P, Vo TH, Aubert L, Fourgeaud M, Michelet-Huot E, et al. Predictive factors for clinically significant pharmacist interventions at hospital admission. Medicine. 2018;97(9):e9865.
Nobrega CR, Lima AF. Procedures’ costs related to outpatient chemotherapy treatment of women suffering from breast cancer. Rev Esc Enferm USP. 2014;48(4):699-705.
Nunes PH, Pereira BM, Nominato JC, Albuquerque EM, Silva LD, Castro IR, et al. Intervenção farmacêutica e prevenção de eventos adversos. Braz J Pharm Sci. 2008;44(4):691-9.
Perlman A, Horwitz E, Hirsh-Raccah B, Aldouby-Bier G, Negev TF, Hochberg-Klein S, et al. Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program. Isr J Health Policy Res. 2019;8(1):19.
Pharmaceutical Society of Australia. Guidelines for pharmacists performing clinical interventions 2018. [cited 2020 Jan 10]. Available from: Available from: https://www.ppaonline.com.au/wp-content/uploads/2019/01/PSA-Clinical-Interventions- Guidelines.pdf
» https://www.ppaonline.com.au/wp-content/uploads/2019/01/PSA-Clinical-Interventions- Guidelines.pdf
Randolph LA, Walker CK, Nguyen AT, Zachariah SR. Impact of pharmacist interventions on cost avoidance in an ambulatory cancer center. J Oncol Pharm Pract . 2018;24(1):3-8.
Rascati KL. Introdução à farmacoeconomia. 1st ed. Porto Alegre (BR): Lippincott Williams & Wilkins; 2010. Charpter 2, Medindo e estimando custos; p. 29-44.
Rodrigues JP, Marques FA, Gonçalves AM, Campos MS, Reis TM, Morelo MR, et al. Analysis of clinical pharmacist interventions in the neurology unit of a Brazilian tertiary teaching hospital. PloS One. 2019;14(1):e0210779.
Saokaew S, Maphanta S, Thangsomboon P. Impact of pharmacist’s interventions on cost of drug therapy in intensive care unit. Pharm Pract (Granada). 2009;7(2):81.
Shen J, Sun Q, Zhou X, Wei Y, Qi Y, Zhu J, et al. Pharmacist interventions on antibiotic use in inpatients with respiratory tract infections in a Chinese hospital. Int J Clin Pharm . 2011;33(6):929-33.
Sjölander M, Lindholm L, Pfister B, Jonsson J, Schneede J, Lövheim H, et al. Impact of clinical pharmacist engagement in ward teams on the number of drug-related readmissions among older patients with dementia or cognitive impairment: An economic evaluation. Res Social Adm Pharm. 2019;15(3):287-91.
Storpirtis S, Mori ALPM, Yochiy A, Ribeiro E, Porta V. Farmácia clínica e atenção farmacêutica. Rio de Janeiro (Brazil): Guanabara Koogan; 2008. 489 p.
Tasaka Y, Yasunaga D, Tanaka M, Tanaka A, Asakawa T, Horio I, et al. Economic and safety benefits of pharmaceutical interventions by community and hospital pharmacists in Japan. Int J Clin Pharm . 2016;38(2):321-9.
Tasaka Y, Tanaka A, Yasunaga D, Asakawa T, Araki H, Tanaka M. Potential drug-related problems detected by routine pharmaceutical interventions: safety and economic contributions made by hospital pharmacists in Japan. J Pharm Health Care Sci. 2018;4(1):1-11.
Yasunaga D, Tasaka Y, Murakami S, Tanaka A, Tanaka M, Araki H. Economic contributions of pharmaceutical interventions by pharmacists: a retrospective report in Japan. J Pharm Policy Pract. 2017;10(1):1-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
